INNATE PHARMA (EPA:IPH) Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) to present at two upcoming investor conferences

Transparency directive : regulatory news

14/09/2011 17:59

PRESS RELEASE

      INNATE PHARMA TO PRESENT AT TWO UPCOMING INVESTOR CONFERENCES

Marseilles, France, September 14, 2011

Innate Pharma SA (Euronext Paris: FR0010331421 - IPH), the innate immunity
company developing first-in-class drugs for cancer and inflammatory diseases,
announces that it will participate in the following investor conferences in the
coming weeks:

* Paris Midcap Event, Palais Brongniard, Paris, on September 22 & 23, 2011;

* BioInvestor Forum, Palace Hotel, San Francisco, on October 25 & 26, 2011.
  During this event, Hervé Brailly, CEO of Innate Pharma, will participate
  in a panel on Cancer Immunotherapy (Immunotherapy: Heal Thyself, Tuesday,
  Octo ber 25th, 10:30am11 :25am, Twin Peaks N/S).

Innate Pharma is committed to meet on a regular basis with the financial
community. Investors can also find updated information on the company's website
(www.innate-pharma.com) and contact the investor relations team by writing to
investors@innate-pharma.com.

                                   -Ends-

About Innate Pharma:
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class
immunotherapy drugs for cancer and inflammatory diseases.

The Company specializes in the development of new monoclonal antibodies
targeting receptors and pathways controlling the activation of innate immunity
cells. Its innovative approach has been validated by licence agreements with two
major pharmaceutical companies, Novo Nordisk A/S and Bristol-Myers Squibb.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate Pharma
is based in Marseilles, France, and had 78 employees as at June 30, 2011.

Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code               FR0010331421
Ticker code             IPH

Disclaimer:
This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Document de Reference prospectus
filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on Innate Pharma's website.
This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country.

For additional information, please contact:

Innate Pharma                     French enquiries
                                  ATCG Press
Laure-Hélène Mercier              Marielle Bricman
Director, Investor Relations      Phone: +33 (0)4 91 25 07 85
Phone: +33 (0)4 30 30 30 87       Mob.: +33 (0)6 26 94 18 53
investors@innate-pharma.com       mb@atcg-partners.com

International enquiries
M:Communications

Phone: +44 (0)20 7920 2330
innatepharma@mcomgroup.com

110914 Next investors meetings

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) to present at two upcoming investor conferences

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories